An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients

Thrombosis Journal

Volumn 4, Issue , 2006, Pages

  Samama, Meyer Michel ^a   Kleber, Franz Xaver ^b  

^a HÔTEL DIEU   (France)

^b UNFALLKRANKENHAUS BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ACUTE DISEASE; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MEDICAL SOCIETY; META ANALYSIS; PRACTICE GUIDELINE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

EID: 33747445536     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-4-8     Document Type: Review

References (45)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Larsen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism. Chest 2004, 126(Suppl 3):338S-400S.
2. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R, Kalodiki E, Myers K, Samama M, Sasahara A: Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001, 20:1-37.
3. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl Med 1999, 341:793-800.
4. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110:874-879.
5. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, ARTEMIS Investigators: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006, 332:325-329.
6. Ageno W, Squizzato A, Ambrosini F, Dentali F, Marchesi C, Mera V, Steidl L, Venco A: Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002, 87:746-750.
7. Panju A, Kahn S, Geerts W, Pineo G, Desjardins L, Turpie A, Glezer S, Sebaldt R: Utilization of venous thromboprophylaxis in acutely ill medical patients in Canada: results from the Canadian registry (CURVE) [abstract]. Blood 2003, 102:abstract # 1813.
8. Tapson VF, Goldhaber SZ: Failure to prophylaxe for deep vein thrombosis: results from the DVT FREE registry [abstract]. Blood 2003, 102:abstract # 1156.
9. Anderson FA Jr, Tapson VF, Decousus H, Spyropoulos AC, Turpie AGG, FitzGerald G, for the IMPROVE investigators: IMPROVE, a multinational observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: a comparison with clinical study patient populations [abstract]. Blood 2003, 102:abstract # 1146.
10. Caprini JA, Arcelus JA, Reyna JJ: Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001, 38(Suppl 5):12-19.
11. Haas SK: Venous thromboembolic risk and its prevention in hospitalised medical patients. Semin Thromb Haemost 2002, 28:577-84.
12. Cohen AT, Alikhan R, Arcelus JI, Bergmann J-F, Haas S, Merli G, Spyropoulos, Tapson VF, Turpie AGG: Assessment of venous thromboembolism risk and the benfits of thromboprophylaxis in mdical patients. Thromb Haemost 2005, 94:750-9.
13. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ: Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005, 352:969-977.
14. Samama MM, Dahl OE, Mismetti P, Quinlan DJ, Rosencher N, Cornelis M, de Vries H, van Beusekom I, Kahan JP: An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica 2006, 91:64-70.
15. Hirsh J: Current anticoagulant therapy - unmet clinical needs. Thromb Res 2003, 109(Suppl 1):S1-8.
16. McCart GM, Kayser SR: Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother 2002, 36:1042-1057.
17. Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O'Brien SE, Carroll JJ. Minden JH, Hudecki SM: Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973, 288:545-551.
18. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR: Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981, 26:115-117.
19. Halkin H, Goldberg J, Madan M, Modan B: Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982, 96:561-565.
20. Cade JF: High risk of the critically ill for venous thromboembolism. Crit Care Med 1982, 10:448-450.
21. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, Arevila-Ceballos N, Fong JH, Sanchez-Martinez R, Dominguez MV, Elizalde-Gonzalez J: Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988, 39:505-513.
22. Gardlund B: Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996, 347:1357-1361.
23. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997, 349:1569-1581.
24. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM: Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986, 16:159-164.
25. Bergmann JF, Caulin C: Heparin prophylaxis in bedriddenpatients. Lancet 1996, 348:205-206.
26. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000, 161:1109-1114.
27. Schuurman B, den Heijer M, Nijs AM: Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense? Neth J Med 2000, 56:171-176.
28. McGarry LJ, Thompson D: Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely ill medical impatients in community practice. Clin Ther 2004, 26:419-430.
29. White RH, Ginsberg JS: Low-molecular-weight heparins: are they all the same? Br J Haematol 2003, 121:12-20.
30. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, Heene DL: Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990, 59:639-650.
31. Bergmann JF, Neuhart E: A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996, 76:529-534.
32. Lechler E, Schramm W, Flosbach CW: The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996, 26(Suppl 2):49-56.
33. Harenberg J, Roebruck P, Heene DL: Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 1996, 26:127-139.
34. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group: Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003, 145:614-621.
35. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H: Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000, 83:14-19.
36. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olson CG, Goldhaber SZ: Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005, 93:76-79.
37. Yalamanchili K, Sukhija R, Sinha N, Aronow WS, Maguire GP, Lehmann SG: Efficacy of unfractionated heparin for thromboembolism prophylaxis in medical patients. Am J Ther 2005, 12:293-9.
38. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG: Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003, 14:341-346.
39. Alikhan R, Cohen AT: A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost 2003, 89:590-591.
40. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
41. Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003, 101:2955-2959.
42. Pechevis M, Detournay B, Pribil C, Fagnani F, Chalanson G: Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health 2000, 3:389-396.
43. Lamy A, Wang X, Kent R, Smith KM, Grafny A: Economic evaluation of the MEDENOX trial: A Canadian perspective. Can Respir J 2002, 9:169-177.
44. Nuijten MJ, Villar FA, Kosa J, Nadipelli V, Rubio-Terres C, Suarez C: Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Value Health 2003, 6:126-136.
45. Lloyd AC, Anderson PM, Quinlan DJ, Bearne A: Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econ 2001, 4:99-113.